Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2005-08-02
2005-08-02
Kemmerer, Elizabeth C. (Department: 1647)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093100, C424S520000, C435S001100, C435S004000, C435S325000
Reexamination Certificate
active
06923959
ABSTRACT:
Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
REFERENCES:
patent: 5876708 (1999-03-01), Sachs
patent: 6001647 (1999-12-01), Peck et al.
patent: 6006752 (1999-12-01), Sykes
patent: 6090400 (2000-07-01), Elliott
patent: 6146653 (2000-11-01), Elliott
patent: 6280957 (2001-08-01), Sayegh et al.
patent: 6412492 (2002-07-01), Sykes
patent: 6703017 (2004-03-01), Peck et al.
patent: 2001/0049827 (2001-12-01), Hunter et al.
patent: 2003/0099622 (2003-05-01), Hering et al.
patent: 97/15310 (1997-05-01), None
patent: 01/39784 (2001-06-01), None
Shizuru et al. Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. Proc Natl Acad Sci USA 97(17): 9555-9560, 2000.
Geggel et al. Effect of peripheral subepithelial fibrosis on corneal transplant topography. J Cataract Refract Surg 22: 135-138, 1996.
Meyers et al. Lung transplantation: current status and future prospects. World J Surg 23: 1156-1162, 1999.
Nenno et al. Cornea transplant statistics in the United States. Refractive & Corneal Surg 7: 467-468, 1991.
Ossevoort et al. Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A. J Immunotherapy 22(5): 381-389, 1999.
Sun et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. Transplantation 61: 1447-1450, 1996.
Wood et al. Reconstructed human skin: transplant, graft of biological dressing? Essays Biochem 29: 65-85, 1995.
Hauben, DJ. The history of free skin transplant operations. Acta Chir Plast. 27(2):66-70, 1985.
Lau et al. Lung transplantation at Duke University Medical Center. Clin Transpl. 327-340, 1998.
Schumacher et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology. 54(5):1042-1050, 2000.
Reemtsma et al. Renal heretotransplantation in man. Ann Surg. 160:384-410, 1964.
Starzl et al. Baboon-to-human liver transplantation. Lancet. 341(8837):65-71, 1993.
Fandrich et al. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med 8(2): 171-178, 2002.
Rifle, G. et al. Donor-derived hematopoietic cells in organ transplantation: a major step toward allograft tolerance? Transplantation. 75(9 Suppl):3S-7S, 2003.
Toungouz et al. Tolerance induction in clinical transplantation: the pending questions.□□Transplantation. 75(9 Suppl):58S-60S, 2003.
Mathew et al. Immunoregulatory role of chimerism in clinical organ transplantation. Bone Marrow Transplantation 28: 115-119, 2001.
Mathew et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transplant Immunol 11: 307-321, 2003.
Monaco AP. Chimerism in organ transplantation: conflicting experiments and clinical observations.□□Transplantation. 75(9 Suppl):13S-16S, 2003.
Kawai, T et al. Long-term islet allograft function in the absence of chronic immunosuppression a case report of a nonhuman primate previously made tolerant to a renal allograft from the same donor. Transplantation. 72(2):351-354, 2001.
Exner, BG et al. Tolerance induction for islet transplantation. Ann Transplant. 2(3):77-80, 1997.
Herve, P. Donor-derived hematopoietic stem cells in organ transplantation: technical aspects and hurdles yet to be cleared. Transplantation. 75(9 Suppl):55S-57S, 2003.
Ikehara, S. New strategies for allogeneic bone marrow transplantation and organ allografts.□□Acta Haematol. 101(2):68-77, 1999.
Lanza et al. Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression. Proc Natl Acas Sci USA 88: 11100-11104, 1991.
Abraham, EJ et al. Human pancreatic islet-derived progenitor cell engraftment in immunocompetent mice. Am J Pathol. 164(3):817-830, 2004.
Bottino R et al. Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol. 16(3):457-474, 2002.
De Pauw, L et al. Infusion of donor-derived hematopoietic stem cells in organ transplantation: clinical data. Transplantation. 75(9 Suppl):46S-49S, 2003.
de Vries-van der Zwan et al. Stem cell transfusion as a new method for the induction of tolerance in organ transplantation. Transplantation Proceedings 29: 1209-1210, 1997.
Peck, et al., Pancreatic stem cells: building blocks for a better surrogate islet to treat type 1 diabetes, 2001,Ann Med. 33: 186-192.
Zulewski, et al. Multipotential Nestin-Positive Stem Cells Isolated From Adult Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes,Diabetes, 50:521-533, 2001.
Zhou, et al., The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype, 2001,Nature Medicinevol. 7, No. 9: 1028-1034.
Bouwens, L.,Transdifferentiation Versus Stem Cell Hypothesis for the Regeneration of Islet Beta Cells in the Pancreas, (1998), Micros. Res. Tech. 43:332-336.
Cornelius, J. et al.,In-Vitro Generation of Islets in Long-Term Cultures of Pluripotent Stem Cells from Adult Mouse Pancreas. (1997), Horm. Metab. Res. 29:271-277.
Xu, G. et al.Exendin-4 Stimulates Both Beta-Cell Replication and Neogenesis, Resulting in Increased Beta-Cell Mass and Improved Glucose Tolerance in Diabetic Rats. (1999), Diabetes. 48:2270-2276.
Ramiya, V. et al.Reversal of Insulin-Dependent Diabetes Using Islets Generated In-Vitro from Pancreatic Stem Cells. (2000), Nature Medicine. 6:278-282.
Stoffers, D. et al.Insulinotropic Glucagon-Like Peptide 1 Agonists Stimulate Expression of Homeodomain Protein IDX-1 and Increase Islet Size in Mouse Pancreas. (2000), Diabetes. 49:741-748.
Ferber, S. et al.Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia. (2000), Nature Medicine. 6:568-572.
Lendahl, U. et al.CNS Stem Cells Express a New Class of Intermediate Filament Protein. (1990), Cell. 60:585-595.
Dahlstrand, J. et al.Characterization of the Human Nestin Gene Reveals a Close Evolutionary Relationship to Neurofilaments. (1992), Journal of Cell Science. 103:589-597.
Hunziker & Stein.Nestin-Expressing Cells in the Pancreatic Islets of Langerhans. (2000), Biochem. & Biophys. Res. Comm. 271:116-119.
Beattie, et al.Acid β-Galactosidase: A Developmentally Regulated Marker of Endocrine Cell Precursors in the Human Fetal Pancreas. (1994). Journ. of Clinical Endocrinology & Metab. 78(5):1232-1240.
Yasumizu, et al.Treatment of type 1 Diabetes mellitus in Non-Obese Diabetic Mice by Transplantation of Allogeneic Bone Marrow and Pancreatic Tissue. (1987), PNAS USA. 84:6555-6557.
Abraham Elizabeth J.
Faustman Denise L.
Habener Joel F.
Thomas Melissa K.
Vallejo Mario
Bunner Bridget E.
Kemmerer Elizabeth C.
Palmer & Dodge LLP
Spar Elizabeth S.
The General Hospital Corporation
LandOfFree
Method of pre-inducing a state of immune tolerance before... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of pre-inducing a state of immune tolerance before..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of pre-inducing a state of immune tolerance before... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461700